Department of Pulmonary and Critical Care Medicine, Xiangya Hospital of Central South University, 410008 Changsha, Hunan, China.
Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, 410008 Changsha, Hunan, China.
Front Biosci (Landmark Ed). 2021 Oct 30;26(10):948-961. doi: 10.52586/4999.
: Corona Virus Disease 2019 (COVID-19) is an acute respiratory infectious disease caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2). The primary pathogenesis is over-activation of the immune system. SARS-CoV-2 continues to mutate and spread rapidly and no effective treatment options are yet available. Mesenchymal stem cells (MSCs) are known to induce anti-inflammatory macrophages, regulatory T cells and dendritic cells. There are a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. : To summarize the pathogenic mechanism of SARS-CoV-2, and systematically formulated the immunomodulation of COVID-19 by MSCs and their exosomes, as well as research progress. : Searching PubMed, clinicaltrials.gov and Chictr.cn for eligible studies to be published or registered by May 2021. Main keywords and search strategies were as follows: ((Mesenchymal stem cells) OR (MSCs)) AND (COVID-19). : MSCs regulate the immune system to prevent cytokine release syndrome (CRS) and to promote endogenous repair by releasing various paracrine factors and exosomes. : MSC therapy is thus a promising candidate for COVID-19.
新型冠状病毒肺炎(COVID-19)是由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的急性呼吸道传染病。其主要发病机制是免疫系统过度激活。SARS-CoV-2 持续快速突变和传播,目前尚无有效的治疗方法。间充质干细胞(MSCs)可诱导抗炎型巨噬细胞、调节性 T 细胞和树突状细胞。目前,针对 COVID-19 的基于细胞的治疗方法的临床研究数量正在迅速增加。
本文旨在总结 SARS-CoV-2 的发病机制,系统阐述 MSCs 及其外泌体对 COVID-19 的免疫调节作用及研究进展。
通过检索 PubMed、clinicaltrials.gov 和 Chictr.cn 数据库,收集截至 2021 年 5 月发表或注册的相关研究,主要检索词和检索策略为:((Mesenchymal stem cells)OR(MSCs))AND(COVID-19)。
MSCs 通过释放各种旁分泌因子和外泌体来调节免疫系统,以防止细胞因子释放综合征(CRS)的发生,并促进内源性修复。
因此,MSC 治疗可能是 COVID-19 的一种有前途的治疗方法。